Previous close | 154.40 |
Open | 154.40 |
Bid | 156.20 |
Ask | 164.00 |
Strike | 190.00 |
Expiry date | 2026-01-16 |
Day's range | 154.40 - 154.40 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.